Author:
Mahurkar S,Moldovan M,Suppiah V,Sorosina M,Clarelli F,Liberatore G,Malhotra S,Montalban X,Antigüedad A,Krupa M,Jokubaitis V G,McKay F C,Gatt P N,Fabis-Pedrini M J,Martinelli V,Comi G,Lechner-Scott J,Kermode A G,Slee M,Taylor B V,Vandenbroeck K,Comabella M,Boneschi F M,King C,
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,Genetics,Molecular Medicine
Reference37 articles.
1. Marziniak M, Meuth S . Current perspectives on interferon beta-1b for the treatment of multiple sclerosis. Adv Ther 2014; 31: 915–931.
2. Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R et al. Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344–352.
3. Roden D, Tyndale R . Pharmacogenomics at the tipping point: challenges and opportunities. Clin Pharmacol Toxicol 2011; 89: 323–327.
4. Byun E, Caillier SJ, Montalban X, Villoslada P, Fernández O, Brassat D et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. JAMA Neurol 2008; 65: 337–344.
5. Comabella M, Craig DW, Morcillo-Suárez C, Río J, Navarro A, Fernández M et al. Genome-wide scan of 500 000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. JAMA Neurol 2009; 66: 972–978.
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献